Translation

Notice: This document is an excerpt translation of the original Japanese document and is for reference purposes only. In the event of any discrepancy between this translated document and the original Japanese document, the latter shall prevail.

Tokyo, April 30, 2021
Alfresa Holdings Corporation

Notice Regarding Revision to Consolidated Performance Forecasts [Prepared on the basis of Japan's Generally Accepted Accounting Principles (GAAP)]

Due to the current business environment, the Company revised its consolidated performance forecasts for the full year ended March 31, 2021 (April 1, 2020 - March 31, 2021), which were previously announced on August 5, 2020.

1. Revision of Consolidated Performance Forecasts for the Full Year Ended March 31, 2021

	Net sales	Operating income	Ordinary profit	Profit attributable to owners of the parent	Basic earnings per share
	¥ Million	¥ Million	¥ Million	¥ Million	Yen
Previous projection (A)	2,631,000	20,900	31,300	19,600	92.60
Revised projection (B)	2,603,000	20,600	31,900	24,500	115.74
Change (B-A)	-28,000	-300	600	4,900	-
Percentage change (%)	-1.1	-1.4	1.9	25.0	-
(Ref.) Results for the full year ended March 31, 2020	2,698,511	47,645	57,170	40,273	190.26

2. Reasons for the Revision of Consolidated Performance Forecasts

Regarding the consolidated financial results for the fiscal year ended March 31, 2021, net sales, operating income, and ordinary profit are generally in line with the previous forecast. Profit attributable to owners of the parent is expected to significantly exceed the previous forecast. The Group gained an extraordinary profit from the sales of some of the investment securities in accordance with its cross-shareholdings policy.

The year-end dividends forecast remains unchanged from the previously announced under our basic policy of shareholders' return.

*Disclaimer regarding the Appropriate Use of Performance Forecasts and Other Notes

The forward-looking statements such as performance forecasts contained herein are forecasts based on information currently possessed by the Company and are based on certain assumptions deemed to be reasonable. Actual performance may differ substantially from these forecasts due to various factors.

About **Alfresa Group**

The Alfresa Group is a leader in Japanese healthcare industry which is dedicated to make its corporate philosophy “we create and deliver a fresh life for all” come true through a wide range of business lines including ethical pharmaceutical wholesaling, OTC drugs wholesaling, pharmaceutical manufacturing, and operating dispensing pharmacies. Alfresa Holdings Corporation (TSE:2784) reported its consolidated revenue of ¥2.7 trillion (US$25 billion) for the fiscal year ended March 31, 2020. For more information, please see: https://www.alfresa.com/eng/index.html